Hims & Hers Health, Inc. (HIMS) Stock Price & Analysis
Hims & Hers Health, Inc. (HIMS) rose 6.66% to USD 28.98 as of June 10, 2026 at 00:52 UTC, according to Nexqual real-time market data.
HIMS last closed at USD 27.17; the session ranged USD 26.02–29.18 on volume of 25,052,858 shares. Market capitalization is $6.71B, with a 52-week range of USD 13.74–70.43 (NYQ). Source: Nexqual, June 10, 2026 at 00:52 UTC.
Key Statistics (as of June 10, 2026 at 00:52 UTC)
| Price | USD 28.98 |
|---|---|
| Change | ▲ 6.66% (up) |
| Previous Close | USD 27.17 |
| Open | USD 27.17 |
| Day Range | USD 26.02 – 29.18 |
| 52-Week Range | USD 13.74 – 70.43 |
| Volume | 25,052,858 shares |
| Market Cap | $6.71B |
| Exchange | NYQ |
Technical Analysis (HIMS)
Nexqual's technical model rates HIMS "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:52 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.65 (neutral) |
| vs SMA50 | Above (USD 25.15) |
| MACD | 0.7 (positive) |
Analyst Ratings (HIMS)
Wall Street analysts rate HIMS "Hold" based on 14 analysts, with a mean price target of USD 26.61 (range USD 21–35), per Nexqual as of June 10, 2026 at 00:52 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 26.61 |
| High Target | USD 35 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 4 / 12 / 0 |
Earnings (HIMS)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD 0.08 |
| Revenue Estimate | $732.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.4 vs est 0.03 ▼ miss |
| 2025-12-31 | USD 0.08 vs est 0.04 ▲ beat |
| 2025-09-30 | USD 0.06 vs est 0.1 ▼ miss |
| 2025-06-30 | USD 0.17 vs est 0.16 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Financials & Fundamentals (HIMS)
| Total Revenue | $2.37B |
|---|---|
| Revenue Growth (YoY) | +3.80% |
| Gross Margin | +72.92% |
| Operating Margin | -7.90% |
| Profit Margin | -0.56% |
| ROE | -2.66% |
| Debt / Equity | 253.73 |
| Current Ratio | 1.69 |
| Total Cash | $750.88M |
| Total Debt | $1.13B |
| Free Cash Flow | $174.31M |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Financial Health Score (HIMS)
Nexqual rates Hims & Hers Health, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:52 UTC.
| Growth | Strong — Revenue +59% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 73%, operating -8% |
| Balance Sheet | Weak — $751M cash vs $1.13B debt |
| Cash Flow | Solid — FCF $174M, 7% margin |
| Efficiency | Critical — ROE -3%, ROA 0.6% |
Ownership (HIMS)
| Insider Ownership | +5.43% |
|---|---|
| Institutional Ownership | +69.94% |
| Shares Outstanding | 223.08M |
| Float | 210.89M |
| Short % of Float | +32.57% |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
Leadership (HIMS)
Hims & Hers Health, Inc. is led by Andrew Dudum (age 37), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 00:52 UTC.
| Co-Founder, Chairman & CEO | Andrew Dudum (age 37) |
|---|---|
| Chief Financial Officer | Oluyemi Okupe (age 39) |
| Chief Operating Officer | Mike Chi (age 45) |
| Chief Technology Officer | Mohamed ElShenawy (age 50) |
| Chief Medical Officer & Director | Patrick Carroll (age 67) |
Major Backers & Investors (HIMS)
Notable institutional backers of Hims & Hers Health, Inc. include Morgan Stanley, Defiance Etfs, LLC, JPMorgan, according to Nexqual as of June 10, 2026 at 00:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 3.98% |
| Defiance Etfs, LLC | 3.33% |
| JPMorgan | 3.24% |
| Bank of America Corporation | 1.95% |
| UBS Group AG | 1.86% |
| Fidelity | 0.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 17.88% |
| Vanguard Group | 16.15% |
| State Street | 4.05% |
| Geode Capital | 2.33% |
Source: Nexqual, June 10, 2026 at 00:52 UTC.
From Hims & Hers Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Healthcare providers, including Providers prescribing on our platform, are permitted to prescribe drugs offered on the platform for "off-label" uses (i.e., uses not approved by the FDA and not described in the product's labeling) because the FDA generally does not regulate the practice of medicine.
- We have relationships with leading health systems in the U.S. including, as of December 31, 2025, Ochsner Health, Mount Sinai Health System, Carbon Health, ChristianaCare Health System, and Hartford Healthcare to provide a clinically focused, telehealth-enabled patient care collaboration.
- Regulatory and/or legal enforcement actions by the Food and Drug Administration (the "FDA"), Department of Health and Human Services, or other international, federal, state, or foreign enforcement authorities could have material adverse consequences on our business or its operations.
- Once we have commenced commercial operations, these operations will be subject to provisions governing FDA-registered manufacturers of active pharmaceutical ingredients ("API"), as well as federal regulations regarding cGMP applicable to API manufacturers.
Partnerships
- Several cosmetics and supplement products have been developed by us in partnership with the applicable manufacturers.
- Organic growth is enhanced by sophisticated omnichannel acquisition strategies meant to target future customers with condition-specific on-ramps at profitable returns on investment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NBIS | Nebius Group N.V. | USD 220.12 | ▼ 3.38% |
| OSCR | Oscar Health, Inc. | USD 27.22 | ▲ 11.06% |
| TEM | Tempus AI, Inc. | USD 48.82 | ▲ 5.15% |
| IREN | IREN LIMITED | USD 54.02 | ▼ 0.61% |
| SOFI | SoFi Technologies, Inc. | USD 16.47 | ▲ 2.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:52 UTC. This page is informational and not investment advice.